Neil Woodford’s Patient Capital could be set to come storming back

Is an 8% jump for Woodford Patient Capital Trust plc (LON: WPCT) a signal to buy?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It seems fair to say that Neil Woodford hasn’t yet replicated his previous success at Invesco Perpetual with his new Woodford Patient Capital Trust (LSE: WPCT).

Initial enthusiasm after the launch in April 2015 pushed the shares up, but that soon waned and the price had dropped to an overall 22% loss by Thursday’s close of play. But it’s only been a little over three years, and just last month Mr Woodford was telling us that it’s still too early to judge.

As a committed long-term investor I’m certainly not going to rush to judgment, and an 8% share price rise on Friday morning has made me sit up and take note.

Thursday’s first-half update had revealed an increase in net asset value from 91.33p to 91.94p during the period, putting the shares on a discount to NAV of 11% at the end of the day. Investment trust shares do tend to trade at discounts, but 11% seems a bit much to me, especially as discounts have typically been narrowing over the past decade.

New valuation

That news was eclipsed Friday by the revelation of a new valuation of Industrial Heat, one of Woodford Patient Capital’s holdings, by its appointed Alternative Investment fund manager Link Fund Solutions.

The new assessment has upped the valuation of Industrial Heat by a whopping 357%, which adds 8.02p to the NAV of the trust’s shares now. That takes it up to 99.96p and the market has duly responded.

But even after Friday morning’s rise, we’re still looking at a discount of nearly 12%, and I really am asking myself if that values Woodford Patient Capital too lowly now.

First-half progress

In that first-half report, chairman Susan Searle pointed out that the period had seen some “demonstrable progress, particularly among the top ten holdings, which has been reflected in some higher valuations.” And Mr Woodford himself pointed out that WPCT was set up with the aim being to invest in “great ideas and help to turn those ideas into great businesses.”

My colleague Jack Tang has stressed WPCT’s poor early performance, and it’s certainly true that probably most investment trust shareholders look for a good track record in a portfolio of proven investments with solid long-term potential.

But with WPCT’s stated ambition of getting in early with new prospects, which are often not listed and are not easy for private investors to buy shares of directly, I really don’t think it’s for people looking for safety from a successful past record.

Unlucky start

The companies WPCT invests in will sometimes suffer calamitous failures; that’s just the nature of the kind of innovative businesses that they are. But WPCT has been unfortunate to be hit by a few failures very early on.

Does that suggest Mr Woodford is losing his touch, or is it just the way fortune and statistics happen to work? I fancy it’s the latter, and I reckon WPCT could do nicely over the next decade and more — it does have “patient” in the name, after all.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

Surprise! This monopoly stock has taken over my Stocks and Shares ISA (again)

Our writer has a (nice) dilemma in his Stocks and Shares ISA portfolio after one incredible growth stock rocketed higher…

Read more »

Investing Articles

10.5% yield – but could the abrdn share price get even cheaper?

Christopher Ruane sees some things to like about the current abrdn share price. But will that be enough to overcome…

Read more »

Investing Articles

£9,000 to invest? These 3 high-yield shares could deliver a £657 annual passive income

The high yields on these dividend shares sail sit well above the FTSE 100 average of 3.6%. Here's why I…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

I’ve got £2k and I’m on the hunt for cheap shares to buy in December

Harvey Jones finally has some cash in his trading account and is hunting for cheap shares to buy next month.…

Read more »

Investing Articles

Down 25% with a 4.32% yield and P/E of 8.6! Is this my best second income stock or worst?

Harvey Jones bought GSK shares hoping to bag a solid second income stream while nailing down steady share price growth…

Read more »

Investing Articles

Here’s how the Legal & General dividend yield could ultimately hit 15%!

The Legal & General dividend yield is already among the best of any FTSE 100 share. Christopher Ruane explores some…

Read more »

Investing Articles

Is December a good time for me to buy UK shares?

This writer is weighing up which shares to buy for his portfolio next month, and one household name from the…

Read more »

Investing Articles

Is it time to dump my Lloyds shares and never look back?

Harvey Jones was chuffed with his Lloyds shares but recent events have made him rethink his entire decision to go…

Read more »